Abstract: The present invention provides humanized anti-CMKLR1 compounds having an agonist capability on the interaction between Resolvin E1 and CMKLR1, and their uses for treating or preventing a disease, in particular wherein the resolution of inflammation is delayed or disrupted.

Abstract: The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.

Abstract: The present invention relates to bifunctional molecules comprising an IL-7 variant and having a particular scaffold and their uses.

Abstract: The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.

Abstract: The present invention relates to the field of perfumery. More particularly, it concerns valuable new chemical intermediates for producing perfuming ingredients. Moreover, the present invention comprises also a process for producing compound of formula (I).

Abstract: The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127.

Abstract: The invention pertains to the field of immunotherapy. The present invention provides new specific anti-CLEC-1A compounds, in particular antibodies. The compounds of the invention are able to specifically binds to CLEC-1A receptor and antagonize the binding of CLEC-1A to its endogenous ligand(s). The use of the compounds of the invention may be useful for treating deleterious conditions.

Abstract: The present invention relates to IL-7 variants, bifunctional molecules comprising it and their uses.

Abstract: The invention pertains to the field of immunotherapy. The present invention provides new anti-SIRPg compounds, which are suitable for the treatment and/or the prevention of autoimmune disorders or diseases.

Abstract: The present invention provides new modified anti-SIRPa antibodies linked to an immunotherapeutic agent which are bifunctional and able to specifically enhance the immune response and uses thereof.

Abstract: New clinical uses of anti-CD127 agents, in particular anti-CD127 antibodies or related compounds for the treatment and/or the prevention of cancer. Methods for treating a patient having a CD127-positive cancer are provided, in particular a CD127-positive leukemia or a CD127-positive solid tumor, by administering to the patient a therapeutic dose of an anti-CD127 agent, the anti-CD127 agent having the capability to enhance the Antibody Dependent Cellular Phagocytosis (ADCP) activity of macrophages targeting CD127-positive cancer cells, and not having Antibody Dependent Cytotoxic Activity (ADCC), in particular against immune cells, more particularly against T cells.

Abstract: The present invention relates to a vaccine composition and its use against a Severe acute respiratory syndrome-related coronavirus.

Abstract: The presently disclosed subject matter provides methods for treating neoplasia using cells comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR)) that specifically targets CD127.

Abstract: The present invention relates to a bifunctional molecule comprising an anti-PD-1 antibody and IL-7 and its uses.

Abstract: The invention pertains to the field of immunotherapy. The present invention provides a new use of anti-CD127 agent, in particular anti-CD127 antibodies or related compounds for the treatment and/or the prevention of cancer. The invention relates to a method for treating a patient having a CD127-positive cancer, in particular a CD127-positive leukemia, by administering to the patient a therapeutic dose of an anti-CD127 agent, the anti-CD127 agent having the capability to enhance the Antibody Dependent Cellular Phagocytosis (ADCP) activity of macrophages targeting CD127-positive cancer cells, and that does not have Antibody Dependent Cytotoxic Activity (ADCC), in particular on immune cells, more particularly on T cells.

Abstract: Described herein are humanized anti-PD-1 antibodies, nucleic acids encoding such, and uses thereof in enhancing immune responses by activating T cells and treating diseases such as cancer and an infectious disease.

Abstract: The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.

Abstract: The present disclosure concerns the use of an anti-SIRPa compound able to inhibit the polarization of anti-inflammatory M2-type macrophages and/or favors pro-inflammatory M1-type macrophages. In a preferred embodiment, such compound is used to treat cancer. Interestingly, this disclosure allows to treat cancer through an indirect pathway involving the immune system.

Abstract: The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127.

Abstract: The present invention pertains to the field of immunotherapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (MDSC) into non suppressive cells, by administering a compound blocking the interaction between SIRPa and CD47 to a patient in need thereof, in order to reduce MDSC-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation.